Sistema de Salut de Catalunya
Institut Català de la Salut
[Koessler T] Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Swiss Cancer Center Leman (SCCL), University of Geneva, Lausanne, Switzerland. European Organisation for Research and Treatment of Cancer, Brussel, Belgium. [Alsina M] European Organisation for Research and Treatment of Cancer, Brussel, Belgium. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Arnold D] European Organisation for Research and Treatment of Cancer, Brussel, Belgium. Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany. [Ben-Aharon I] European Organisation for Research and Treatment of Cancer, Brussel, Belgium. Division of Oncology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel. [Lutz MP] European Organisation for Research and Treatment of Cancer, Brussel, Belgium. Caritasklinikum, Saarbrucken, Germany. [Obermannova R] European Organisation for Research and Treatment of Cancer, Brussel, Belgium. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic. Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
Vall d'Hebron Barcelona Hospital Campus
2022-06-15T11:00:45Z
2022-06-15T11:00:45Z
2021-09
Biliary tract cancer; Colorectal cancer; Drug development
Cáncer del tracto biliar; Cáncer colorrectal; Desarrollo de fármacos
Càncer del tracte biliar; Càncer colorectal; Desenvolupament de fàrmacs
Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.
Open Access funding provided by Université de Genève.
Article
Versió publicada
Anglès
Avaluació de resultats (Assistència sanitària); Immunoteràpia; Aparell digestiu - Càncer - Tractament; DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
Springer Nature
British Journal of Cancer;125
https://doi.org/10.1038/s41416-021-01474-y
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
